Clinical outcomes of patients with mitral prosthetic valve obstructive thrombosis treated with streptokinase or tenecteplase

Agent of choice for thrombolytic therapy (TT) in prosthetic valve thrombosis (PVT) is unknown. 84 mitral obstructive-PVT episodes treated with TT (43: Tenecteplase; 41: Streptokinase) were included in this prospective study. The incidence of primary end-point (CCS: complete clinical success, defined...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiran, G. Ravi, Chandrasekhar, P., Mohammad Ali, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322749/
https://www.ncbi.nlm.nih.gov/pubmed/34154758
http://dx.doi.org/10.1016/j.ihj.2021.02.005
_version_ 1783731120784801792
author Kiran, G. Ravi
Chandrasekhar, P.
Mohammad Ali, S.
author_facet Kiran, G. Ravi
Chandrasekhar, P.
Mohammad Ali, S.
author_sort Kiran, G. Ravi
collection PubMed
description Agent of choice for thrombolytic therapy (TT) in prosthetic valve thrombosis (PVT) is unknown. 84 mitral obstructive-PVT episodes treated with TT (43: Tenecteplase; 41: Streptokinase) were included in this prospective study. The incidence of primary end-point (CCS: complete clinical success, defined as complete or partial hemodynamic success with no complications or surgery) was 84.5% with recurrent PVT as a sole predictor. Bleeding and embolic manifestations were noted in 8.3% and 4.7% of episodes respectively. Tenecteplase use was associated with lower complication rate and a mitral EOA of <0.74 cm(2) at presentation predicts the need for extended thrombolysis (accuracy, 78.6%).
format Online
Article
Text
id pubmed-8322749
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83227492021-07-31 Clinical outcomes of patients with mitral prosthetic valve obstructive thrombosis treated with streptokinase or tenecteplase Kiran, G. Ravi Chandrasekhar, P. Mohammad Ali, S. Indian Heart J Research Brief Agent of choice for thrombolytic therapy (TT) in prosthetic valve thrombosis (PVT) is unknown. 84 mitral obstructive-PVT episodes treated with TT (43: Tenecteplase; 41: Streptokinase) were included in this prospective study. The incidence of primary end-point (CCS: complete clinical success, defined as complete or partial hemodynamic success with no complications or surgery) was 84.5% with recurrent PVT as a sole predictor. Bleeding and embolic manifestations were noted in 8.3% and 4.7% of episodes respectively. Tenecteplase use was associated with lower complication rate and a mitral EOA of <0.74 cm(2) at presentation predicts the need for extended thrombolysis (accuracy, 78.6%). Elsevier 2021 2021-02-18 /pmc/articles/PMC8322749/ /pubmed/34154758 http://dx.doi.org/10.1016/j.ihj.2021.02.005 Text en © 2021 Cardiological Society of India. Published by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Brief
Kiran, G. Ravi
Chandrasekhar, P.
Mohammad Ali, S.
Clinical outcomes of patients with mitral prosthetic valve obstructive thrombosis treated with streptokinase or tenecteplase
title Clinical outcomes of patients with mitral prosthetic valve obstructive thrombosis treated with streptokinase or tenecteplase
title_full Clinical outcomes of patients with mitral prosthetic valve obstructive thrombosis treated with streptokinase or tenecteplase
title_fullStr Clinical outcomes of patients with mitral prosthetic valve obstructive thrombosis treated with streptokinase or tenecteplase
title_full_unstemmed Clinical outcomes of patients with mitral prosthetic valve obstructive thrombosis treated with streptokinase or tenecteplase
title_short Clinical outcomes of patients with mitral prosthetic valve obstructive thrombosis treated with streptokinase or tenecteplase
title_sort clinical outcomes of patients with mitral prosthetic valve obstructive thrombosis treated with streptokinase or tenecteplase
topic Research Brief
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322749/
https://www.ncbi.nlm.nih.gov/pubmed/34154758
http://dx.doi.org/10.1016/j.ihj.2021.02.005
work_keys_str_mv AT kirangravi clinicaloutcomesofpatientswithmitralprostheticvalveobstructivethrombosistreatedwithstreptokinaseortenecteplase
AT chandrasekharp clinicaloutcomesofpatientswithmitralprostheticvalveobstructivethrombosistreatedwithstreptokinaseortenecteplase
AT mohammadalis clinicaloutcomesofpatientswithmitralprostheticvalveobstructivethrombosistreatedwithstreptokinaseortenecteplase

Ejemplares similares